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Resumo 
 
Diabetes mellitus tipo 2 (DM2) é um importante problema de saúde, com 
415 milhões de pessoas diagnosticadas em todo o mundo. Foram descritas 
evidências quanto à sua associação com vários tipos de cancro, incluindo o cancro 
gástrico. Foram sugeridas algumas hipóteses para explicar como a DM2 poderia 
aumentar o risco de desenvolvimento de cancro, como por exemplo a 
hiperglicemia, hiperinsulinemia, stress oxidativo, distúrbios vasculares e um 
estado de inflamação crónica basal. O cancro gástrico é o quinto cancro mais 
comum no mundo e é a terceira principal causa de morte por cancro. O cancro 
gástrico é frequentemente associado à infeção por Helicobacter pylori, e essa 
inflamação desempenha um papel central no processo carcinogénico. Esse estado 
inflamatório crónico, relacionado com o desequilíbrio angiogénico, stress oxidativo 
e com a sinalização metabólica, sugere que a DM2 pode ser um importante fator 
de risco na iniciação e progressão do cancro gástrico, no entanto serão necessários 
mais estudos. 
Foi estudada uma coorte constituída por dois grupos de pacientes, um grupo 
com cancro gástrico e DM2 (n=22) e outro grupo controlo com cancro gástrico e 
sem DM2 (n=21). Foi realizada uma análise imunohistoquímica utilizando um 
anticorpo contra CD31, para avaliar a densidade dos vasos. Foi também realizada 
uma coloração histoquímica com Sirius Red, para determinar a percentagem de 
fibrose no tumor e na mucosa normal adjacente. Com base na avaliação do 
infiltrado de células inflamatórias no tumor e da percentagem de estroma no 
tumor, realizou-se uma avaliação semi-quantitativa denominada “Glasgow 
Microenvironment Score”. Além disso, o score para o prognóstico de Glasgow, que 
é amplamente conhecido como um marcador baseado na inflamação sistémica, foi 
determinado para cada paciente. Os grupos foram estabelecidos de forma a que as 
características clinico-patológicas dos pacientes fossem semelhantes e a principal 
diferença fosse a presença ou ausência de diabetes. Relacionou-se a diabetes com 
a sobrevida de cada paciente, e também de forma estratificada pelos diferentes 
scores de Glasgow Microenvironment Score e Glasgow Prognostic Score.  
Verificamos não existirem diferenças significativas tanto nas características 
clinico-patológicas, como na inflamação sistémica e tumoral de cada paciente e 
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também na sobrevida a dois e cinco anos, nem entre grupos nem quando 
estratificados pelos diferentes scores. Na avaliação da densidade vascular e da 
fibrose, verificou-se apenas diferenças significativas entre a área adjacente normal 
dos controlos e a área tumoral dos diabéticos.   
Mais investigação será necessária para verificar estes resultados e perceber 
se estes marcadores poderão ser bons indicadores de prognostico destas 
patologias.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: cancro gástrico; diabetes mellitus; inflamação; angiogénese; 
fibrose.
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Abstract 
 
Type 2 Diabetes mellitus (DM2) is a major health problem, with 415 million 
people diagnosed worldwide. Evidence regarding its association with various types 
of cancer has been reported, including GC. Some hypotheses have been suggested 
to explain how DM2 could enhance the risk of cancer development, such as 
hyperglycemia, hyperinsulinemia, oxidative stress, vascular disturbances and a 
chronic low inflammation state. Gastric cancer (GC) is the fifth most common 
cancer worldwide and ranks as the third leading cause of cancer-related death. GC 
is frequently associated with infection by Helicobacter pylori and inflammation 
plays a central role in the carcinogenic process. Such chronic inflammatory state, 
linked with angiogenesis imbalance, oxidative stress and metabolic signaling, 
suggests that also DM2 might be a major risk factor in initiation and progression 
of GC, demanding further investigation.  
A series of GC from DM2 (n=22) and control (n=21) patients were studied. 
Immunohistochemistry (IHC) using antibodies against CD31 performed, to assess 
density of vessels. Histochemical staining with Sirius red was performed to 
determine the percentage of fibrosis in the tumor and non-neoplastic adjacent 
mucosa. Based on assessment of tumor inflammatory cell infiltrate and tumor 
stroma percentage, a semi-quantitative evaluation of Glasgow Microenvironment 
Score was performed. Also, Glasgow Prognostic Score, that is widely known as a 
systemic inflammatory-based marker, was determined for each patient.  
Additionally, the Glasgow prognostic score, which is widely known as a marker 
based on systemic inflammation, was determined for each patient. The groups were 
established so that the clinical-pathological characteristics of the patients were 
similar and the main difference was the presence or absence of diabetes. Diabetes 
was related to the survival of each patient, and also stratified by the different 
scores, Glasgow Microenvironment Score and Glasgow Prognostic Score. 
We verified that there were no significant differences in the clinical and 
pathological characteristics, as well as in the systemic and tumoral inflammation 
of each patient and also in the survival at two and five years, neither between 
groups nor when stratified by the different scores. In assessing vascular density 
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and fibrosis, there were only significant differences between the normal adjacent 
area of the controls and the tumor area of the diabetics. 
More research will be needed to verify these results and to see if these 
markers could be good indicators of the prognosis of these pathologies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords:  gastric cancer; diabetes mellitus; inflammation; angiogenesis; fibrosis. 
  
Página | xix  
 
Poster presentation under the scope of this thesis 
 
Rocha, R., Rodrigues, I., Gullo, I., Gonçalves, G., Pedro, J., Carvalho, D., Carneiro, 
F., Soares, R., Andrade, S. Angiogenesis and inflammation at the crossroads 
between diabetes and cancer. 12th YES Meeting (2017). 
 
 
  
  
Página | xxi  
 
List of Figures 
 
Figure 1 - Morphological heterogeneity in GC. Several histological patterns are 
represented according to the Laurén Classification. ........................................... 10 
Figure 2 - Interrelationship between pathological mechanisms and modifiable and 
non-modifiable risk factors involved in diabetes, obesity and cancer. IGF, insulin-
like growth factor. ............................................................................................. 21 
Figure 3 - Blood glucose at the surgery. ............................................................ 37 
Figure 4 – Kaplan-Meier survival curves of the studied cohort at 2 and 5-years .. 41 
Figure 5 – Kaplan-Meier survival curves at 2 and 5-years, of all patients in study, 
stratified by GMS score. ..................................................................................... 42 
Figure 6 – Kaplan-Meier survival curves at 2 and 5-years, of all patients in study, 
stratified by GPS score. ...................................................................................... 42 
Figure 7 - Fibrosis staining in (A) control patient and (B) diabetic patient. ......... 43 
Figure 8 - Fibrotic status of control (n=21) and diabetic (n=22) gastric cancer 
groups, by Sirius Red staining. .......................................................................... 44 
Figure 9 - Microvessel staining: microvessel were highlighted by staining 
endothelial cells (staining against CD31 antibody). ............................................ 45 
Figure 10 - Gastric cancer microvessel density of control (n=21) and diabetic group 
(n=22) assessed by CD31 staining.. ................................................................... 46 
   
  
Página | xxiii  
 
List of Tables 
 
Table 1- Blood glucose levels to diagnose diabetes mellitus 
17
. ............................ 5 
Table 2 – Heterogeneity of histopathological classification systems in gastric 
cancer by Laurén and World Health Organization. Adapted from 
27
..................... 11 
Table 3 - T-staging of gastric cancer. ................................................................ 13 
Table 4 – Demographic and clinicopathological characteristics of the studied 
cohort (n=43). ................................................................................................... 38 
Table 5 - Assessment of Glasgow Microenvironment Score of control group (n=21) 
and diabetic group (n=22). ................................................................................ 40 
Table 6 - GPS scoring of control group (n=21) and diabetic group (n=22) .......... 40 
Table 7 - Overall survival of the studied cohort ................................................. 41 
 
 
 
 
  
  
  
Página | xxv  
 
List of Abbreviations 
 
AJCC    American Joint Committee on Cancer 
AKT   Protein kinase B 
AMP   Adenosine Monophosphate-activated Protein 
ATP   Adenosine triphosphate 
BMI   Body mass index 
CC1   Cell conditional 1 
CD31   Cluster of differentiation 31  
CRP   C-reactive protein 
CT   Computed tomography 
DAB   3,3'-diaminobenzidine 
DM   Diabetes mellitus 
DNA   Deoxyribonucleic acid 
EBV   Epstein-barr virus  
EC   Endothelial cells 
ECM   Extracellular matrix  
ERK   Extracellular Signal-regulated Kinase 
FPG   Fasting plasma glucose  
GC   Gastric cancer 
GCA   Gastric cardia 
GLUT   Glucose transporter  
GMS   Glasgow microenvironment score 
GNCA   Gastric non-cardia 
Página | xxvi  
 
GPS   Glasgow prognostic score 
HbA1c  Hemoglobin A1c  
HE   Hematoxylin and eosin 
HER2   Human epidermal growth factor Receptor 
HRP   Horseradish peroxidase 
IGF   Insulin-like growth factor 
IL   Interleukin  
IR   Insulin resistense  
KM   Klintrup–Mäkinen   
LKB1   Liver kinase B1 
MALT   Mucosa-associated lymphoid tissue   
MAPK   Mitogen-activated protein kinase 
MRI   Magnetic resonance imaging   
mTOR   Mammalian target of rapamycin 
NIDDM  Non-insulin-dependent diabetes mellitus  
OGTT   Oral glucose tolerance test 
PFKFB3  6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3  
PI3K   Phosphoinositide 3-kinase 
PlGF   Placental growth factor 
PPAR   Peroxisome Proliferator-Activated Receptor   
RNS   Reactive nitrogen species  
ROS   Reactive oxygen species 
SRC   Signet ring cell   
TNF   Tumor necrosis factor 
TNM   Tumor-Node-Metastasis 
  
Página | xxvii  
 
TSP   Tumor stroma percentage 
TZD   Thiazolidinediones   
UICC   International Union for Cancer Control 
US   Ultrasonography 
VEGF   Vascular endothelial growth factor 
VEGFR   Vascular endothelial growth factor receptor 
WHO   World Health Organization  
 
  
 
 
 INDEX 
INTRODUCTION 1 
1. Diabetes mellitus 3 
2. Gastric cancer 6 
2.1. Laurén classification 9 
2.2. World Health Organization (WHO) classification 9 
2.3. Prognostic and predictive biomarkers for gastric cancer 11 
3. Diabetes and gastric cancer 14 
3.1. Shared risk factors 15 
3.2. Hyperglycemia 16 
3.3. H. pylori infection 16 
3.4. Salt intake 17 
3.5. Anti-diabetic drugs and cancer 17 
3.6. Biological links between diabetes and gastric cancer 18 
AIMS 23 
MATERIAL AND METHODS 27 
1. Study design 29 
2. Histology review 30 
2.1. Assessment of Glasgow Microenvironment Score 30 
3. Assessment of GPS 31 
4. Fibrosis evaluation 31 
5. Microvessel density evaluation 31 
5.1. Immunohistochemistry 31 
5.2. Immunohistochemistry Scoring 33 
6. Statistical analysis 33 
Página | 30  
 
RESULTS 35 
1. Cohort characteristics 37 
2. Significance of DM2 for GMS, GPS and outcome of GC 39 
2.1. DM2 and GMS 39 
2.2. DM2 and GPS 40 
2.3. DM2 and GC outcome 41 
3. Fibrotic status 43 
4. CD31 staining analysis 45 
DISCUSSION 47 
CONCLUSION AND FUTURE PERSPECTIVES 53 
REFERENCES 57 
 
 
 
  
 
 
 
Introduction 
 
  
  
  
Página | 3 
 
1. Diabetes mellitus 
Diabetes mellitus (DM) is one of the most prevalent chronic diseases 
worldwide and one of the main global health emergencies of the 21
st
 century. 
Recent studies estimate that approximately 415 million people worldwide suffer 
from DM, and its prevalence is expected to rise to 642 million by 2040 
1
. In 2015, 
it was estimated that DM affects 59,8 million in Europe, with Portugal accounting 
for approximately 1 million (13% of its population) 
1
.  
There are three major types of diabetes:  
Type 1 DM (DM1), accounting for approximately 7 to 12% of the total cases
1
. 
It is characterized by an autoimmune destruction of pancreatic β-cells, leading to 
absolute insulin deficiency and, consequently, to the total dependence on 
exogenous insulin to sustain life 
2
. In the past, DM1 was also referred to as juvenile 
onset diabetes, with a peak incidence between the ages of 8 and 14 
3,4
;  
Type 2 DM (DM2), accounting for almost 87-91% of the diabetic population
1
, 
also known as non-insulin-dependent diabetes mellitus (NIDDM) or as adult-onset 
diabetes, is characterized by insulin resistance which may be combined with 
relatively reduced insulin secretion levels 
5,6
. DM2 is a complex pathology involving 
multiple genetic and environmental factors, such as sedentary lifestyle, eating 
habits, and some genetic polymorphisms related to β-cells function and insulin 
secretion. The disease is usually associated with obesity, insulin resistance, 
metabolic syndrome and dysfunction of β-cells 7,8. In DM2, the use and storage of 
carbohydrates are altered, causing compensatory hyperglycemia and 
hyperinsulinemia which later results in progressive deficiency of insulin secretion 
6,7,9
. Persistent hyperglycemia may lead to glucotoxicity, a critical factor in the 
pathogenesis of long-term complications of diabetes. Associated mechanisms 
include the harmful effects of advanced glycosylation products and activation of 
protein kinase C 
7,8
. 
Gestational DM, which only occurs during pregnancy and is related to a 
degree of glucose intolerance 
10,11
. Represents 17.8% of all pregnancies 
12
, and it is 
also an important risk factor for type 2 diabetes in women that have been 
diagnosed with gestational diabetes 
13,14
.  
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Glucose levels are usually regulated by insulin at the following restricted 
limits: 60-100 mg/dl. Diabetes mellitus is not a simple pathology, but rather a set 
of metabolic alterations that share a common characteristic: hyperglycemia. This 
pathology is caused by changes in insulin secretion and/or action 
2,6-8
. Since 
hyperglycemia and hyperinsulinemia coexist for a long-time due to insulin 
resistance (IR) in peripheral tissues, hyperglycemia is the most prominent clinical 
syndrome that characterizes DM2. Patients require insulin treatment only when 
their cells are out-of-function and cause a deficiency of endogenous insulin 
15
. 
There are many ways that are used to diagnose diabetes 
2
, glycated 
hemoglobin (HbA1c), Fasting Plasma Glucose (FPG) and Oral Glucose Tolerance 
Test (OGTT).  
Measurement of glycated hemoglobin is essential to the supervision of 
patients with diabetes. HbA1c is used to screen long-term glycemic control, adjust 
therapy, assess the quality of diabetes care and predict the risk for the development 
of complications. HbA1c is a specific glycated hemoglobin that results from the 
attachment of glucose to the N-terminal valine of the hemoglobin β-chain 16.The 
HbA1c test measures the average blood glucose for the past 2 to 3 months, and 
diabetes is diagnosed when HbA1c is greater than or equal to 6.5% 
2
. 
  FPG test measures fasting blood glucose levels, which means that the 
subjects had nothing to eat or drink (except water) for at least 8 hours before the 
test. Diabetes is suspected if fasting blood glucose is higher than or equal to 126 
mg/dl.   
The OGTT test is used to determine whether the body has difficulty 
metabolizing the intake of sugar/carbohydrates. The patient is asked to ingest a 
high glucose drink and their blood glucose level is measured before and at time 
points after the sugary drink is taken. Further blood samples may be taken either 
at regular intervals of say 30 or 60 minutes or one single test after 2 hours. 
Diabetes is diagnosed at 2h blood glucose of upper than or equal to 200 mg/dl 
2
. 
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Table 1- Blood glucose levels to diagnose diabetes mellitus 
17
. 
 HbA1c FPG OGTT 
Normal 
< 5.7% 
(< 39 mmol/L) 
< 100 mg/dl 
(< 5.6 mmol/L) 
< 140 mg/dl 
(< 7.8 mmol/L) 
Prediabetes 
5.7-6.4% 
(39-47 mmol/L) 
100-125 mg/dl 
(5.6-6.9 mmol/L) 
140-199 mg/dl 
(7.8-11.0 mmol/L) 
Diabetes 
≥ 6.5% 
(> 48 mmol/L) 
≥ 126 mg/dl 
(> 7.0 mmol/L) 
≥ 200 mg/dl 
(> 11.1 mmol/L) 
HbA1c = glycated hemoglobin; FPG = Fasting Plasma Glucose; OGTT = Oral Glucose Tolerance Test 
 
Chronic hyperglycemia and the occurrence of metabolic imbalances may 
be associated with secondary lesions in several organs 
6-8
. This metabolic imbalance 
is caused by two main factors, the pancreas not being able to produce enough 
insulin or the cells not responding to the insulin produced by the pancreas, or both. 
It is about quantity and quality of insulin that the pancreas produces 
10,18
. On the 
other hand, intermediate hyperglycemia consists of the presence of high glucose 
levels that do not reach the values of diabetes but greatly increase the risk of 
developing the disease 
6-8
. The chronic hyperglycemia of diabetes is associated with 
long-term damage, dysfunction and failure of various organs, macro- (damage to 
larger arteries) and microvasculature (damage to small blood vessels), eyes, 
kidneys, nerves, heart and blood vessels 
10,15
. Therefore, more work is needed to 
better understand the mechanisms in diabetic patients to allow earlier diagnoses 
and provide better strategies for diabetes treatment 
15
. Also, associated with this 
condition are the high triglyceride and cholesterol levels in blood (dyslipidemia), 
that could increase the vascular wall injury and the pro-thrombotic state. When the 
hemostasis of the body is out of balance, high pressure in the arteries occurs and 
a pro-inflammatory condition is installed in the organs 19.  
Moreover, DM2 is strongly associated with cardiovascular disease and 
various kinds of cancer as found by several epidemiological and experimental 
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studies and meta-analyses 
20
. There is still much unknown regarding the 
mechanisms by which DM2 enhances the risk of developing cancer. However, some 
hypotheses have been presented, such as the presence, in these patients, of 
hyperglycemia, hyperinsulinemia, oxidative stress, vascular disturbances and a 
chronic low inflammation state. There may be also site-specific mechanisms in 
some particular organs, that promote the development of cancer in a specific 
organ. In fact, there is a growing number of papers that associate diabetes with 
gastric cancer 
21-23
. 
 
2. Gastric cancer 
Results from GLOBOCAN 
24
 show that, in 2012, 14.1 million new cases of 
cancer were diagnosed worldwide (excluding non-melanoma skin cancer) and there 
were 8.2 million deaths associated to cancer. The incidence and cancer-related 
deaths were slightly more frequent among men, with a prevalence of 53% and 57%, 
respectively, than women. 
Cancer involves a pathological failure in the processes that controls cell 
proliferation, differentiation and death. Commonly, the malignant cells form a 
tumor arise from epithelial tissue – carcinoma – or from glandular epithelium – 
adenocarcinoma. While having certain characteristics in common, different types 
of cancers may have very different causes and show widely different responses to 
treatment 
25
. 
Gastric cancer (GC) is the fifth most common cancer worldwide, only after 
cancers of the lung, breast, colorectal and prostate, and it ranks as the third leading 
cause of cancer-related death. Based on GLOBOCAN, almost one million new cases 
of stomach cancer were estimated to have occurred in 2012  (952,000 cases, 6.8% 
of the total) 
24
. Most GCs are gastric adenocarcinomas, which are malignant 
epithelial neoplasms. However, GC is a highly heterogeneous entity with respect to 
patterns of architecture and growth, cell differentiation, histogenesis and 
molecular pathogenesis 
26
. 
Tumor heterogeneity can be due to genetic alterations, epigenetic events, 
interactions between tumor cells and the microenvironment, and also interactions 
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between the different tumor cell clones/populations within the tumor 
27
. The 
heterogeneity of GC is known to vary widely across geographical regions 
24
, 
macroscopic and microscopic features, and also molecular alterations 
27
. 
Additionally, phenotypic and molecular variety includes not only interpatient 
variations, but also intratumor variations 
27
. 
 Incidence of GC remains very high in numerous countries from Asia, Latin 
America and Central and Eastern Europe, whereas in North America and in most 
Western European countries it is no longer a common cancer 
28,29
. In Portugal, 
despite a steady decline in mortality, 
28,30
 gastric cancer rates 
24
 are among the 
highest in Europe, especially in the North of the country 
31
.  
The fundamental reasons for these geographical differences are likely multi-
factorial, and may involve differences in infectious etiology (e.g., Helicobacter 
pylori, Epstein-Barr Virus), environmental risk factors (diet, obesity), and 
population-specific differences in host genetic polymorphisms 
32
. If gastric cancer 
is detected at an early stage, the 5-years survival is approximately 90% 
33
, but 
because there are no specific symptoms at this stage when the disease is surgically 
curable, most patients have locally advanced or metastatic disease, which has a 
median survival of 24 month and 5-years survival of less than 15% 
32,34,35
.  
Adequate surgical resection, or endoscopic resection in selected early-stage 
tumors 
36
 , are the mainstays of the curative approach. Fluoropyrimidine- and 
platinum-based chemotherapeutic regimens are recommended in the neoadjuvant 
or adjuvant setting, and as the first-line treatment in patients with advanced and 
unresectable GC 
37
.  Trastuzumab (anti-HER2; human epidermal growth factor 
receptor 2) 
38
 and ramucirumab (anti-VEGFR2; vascular endothelial growth factor 
receptor 2) 
39,40
 monoclonal antibodies have recently been approved as clinically 
validated molecular targeted therapies in the treatment of advanced/metastatic GC. 
However, these therapies offer only a limited survival advantage of a few months 
(1.5–2.2 months) 38-40 and, to date, except for HER2, there are no predictive 
biomarkers of tumor response to targeted therapies in GC 
41
. 
The epidemiological and molecular features of gastric cancer differ 
according to the histological type and location of the tumor 
35,42
. Among clinical risk 
factors for GC, which include smoking, high-salt diet, high intake of meats, and 
bile reflux, infection with Helicobacter pylori is a leading factor 
43,44
. On the basis of 
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improved estimates from prospective studies, 89% of new non-cardia GC cases are 
attributable to H. pylori worldwide 
45
.  
Incidence rates showed differences according to tumor topography 
46,47
, with 
upward trends in cardia incidence 
48,49
. Cardia tumors, the upper part of the stomach 
contiguous to esophagus, may be related to gastroesophageal reflux, whereas the 
majority of non-cardia gastric cancers are attributable to chronic mucosal infection 
by Helicobacter pylori 
46
. Apart from H. pylori infection, nutritional exposures are 
implicated as risk factors for noncardia gastric cancer. Consumption of salt is 
associated with increased incidence, whereas consumption of fresh fruits and 
vegetables protective role 
50
.  
Lin et al. 
51
 showed, in a population-based cohort study, conducted in the 
United States, a statistically significant 89% increased risk of gastric cardia (GCA) 
in diabetics, but no increase in risk of gastric non-cardia (GNCA). Obesity-mediated 
hyperinsulinemia could be one of the possible mechanisms for this increased risk 
52,53
 However, this study also showed that the risk remained significantly higher 
even after adjusting for body mass index (BMI) or when stratified by BMI categories. 
This result suggests a different carcinogenic mechanism, independent of obesity, 
for diabetes-related GCA. Recent studies have shown that H. pylori infection may 
be associated with higher risk of GCA also 
54
. However, the role of H. pylori in GCA 
was not evaluated.  
H. pylori is classified as a carcinogenic agent by the WHO 
24
, which states 
that colonization of the stomach epithelia leads to an inflammatory precancerous 
cascade consisting of chronic gastritis, atrophic gastritis, intestinal metaplasia, 
dysplasia and finally adenocarcinoma 
35
. The prevalence differs with the geographic 
regions, age, socio-economic status, education level, living environment and 
occupation 
55
. Among infected individuals, approximately 10% develops peptic 
ulcer disease, 1–3% progresses to GC, and 0.1% develops mucosa-associated 
lymphoid tissue (MALT) lymphoma 
42,56
.  
Gastric cancers can be divided into different subtypes at the histological 
level, of which the two most popular classification systems were proposed by 
Laurén in 1965 
57
 and by World Health Organization in 2010 
58
 (Table 2). Other 
classifications were also proposed by Ming and Goseki 
59
. 
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2.1. Laurén classification 
Since 1965, the Laurén classification of gastric cancer has been the most 
frequently used and the most studied classification for gastric adenocarcinoma. 
Laurén separated the histology of gastric cancer (Figure 1) into two groups, the 
intestinal type (clearly defined glandular structures) and the diffuse type 
(consisting of individually infiltrating neoplastic cells). Later, the indeterminate 
type was included to describe an uncommon/mixed histology 
57
. Signet ring cell 
(SRC) carcinoma is included in the diffuse type 
59
. In some studies, the intestinal 
type has been described to be the most common, followed by the diffuse and finally 
by the indeterminate type 
60,61
.  
The intestinal type is more frequently observed in older patients and follows 
multifocal atrophic gastritis, that is usually accompanied by intestinal metaplasia 
and leads to cancer via dysplasia. Thus, intestinal metaplasia is considered a 
dependable morphological marker for gastric cancer risk. The diffuse type occurs 
more commonly in young patients, can be multifocal, is not often accompanied by 
intestinal metaplasia and can be hereditary 
44
. 
2.2. World Health Organization (WHO) classification 
In 2010, the World Health Organization (WHO) released a classification that 
appears to be the most detailed of all pathohistological classification systems. This 
classification includes not only the adenocarcinoma of the stomach but also other 
types of tumors of the digestive system 
58
. 
The gastric adenocarcinoma type is divided into papillary, tubular, mucinous 
and poorly cohesive, which includes the signet ring cell carcinoma, and that can be 
compared to the indeterminate type in the Laurén classification 
58
. In the WHO 
classification, tubular adenocarcinoma is the most common type of gastric cancer, 
followed by the papillary and mucinous types. The signet-ring cell carcinoma 
accounts for approximately 10% of gastric cancers and is defined by the presence 
of signet ring cells in over 50% of the tumor 
58
. 
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A B 
C D 
E F 
Figure 1 - Morphological heterogeneity in GC. Several histological patterns are represented according 
to the Laurén Classification. A – intestinal type. HE. Original magnification: x200; B – intestinal type. 
HE. Original magnification: x400. C - diffuse type. HE. Original magnification: x200; D – diffuse type. 
HE. Original magnification: x400; E - mixed type. HE. Original magnification: x200; F – mixed type. 
HE. Original magnification: x400. 
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Table 2 – Heterogeneity of histopathological classification systems in gastric cancer by Laurén and 
World Health Organization. Adapted from 
27
. 
 
Laurén Classification WHO Classification 
Intestinal type 
Papillary adenocarcinoma 
Tubular adenocarcinoma 
Mucinous adenocarcinoma 
Diffuse type 
Poorly cohesive, SRC phenotype 
Poorly cohesive, other cell types 
Mixed type Mixed type 
Indeterminate type 
Undifferentiated 
Rare variants 
 
2.3. Prognostic and predictive biomarkers for gastric cancer 
The tumor-node-metastasis (TNM), is the global standard to stage solid 
tumors, extensively used by clinicians, accepted by the American Joint Committee 
on Cancer (AJCC) and the International Union for Cancer Control (UICC). The system 
codes the extent of the primary tumor (T), regional lymph nodes involvement (N), 
and distant metastases (M) and categorized a stage grouping based on T, N, and 
M 
62,63
. TNM classification has become the principal method for prognosis 
assessment in gastric cancer (Table 3) 
64
. Although these variables are, indeed, 
effective and are widely applied, they cannot provide sufficient prognostic 
information 
65
.  
Histologically, cancer tissues are composed of parenchyma and stroma, and 
tumor stroma constitutes a microenvironment for cancer cells. Accumulating 
evidence proposes that tumor stroma significantly contributes to tumor growth and 
dissemination 
66,67
, angiogenesis 
68
, immune evasion 
69,70
 and chemotherapy 
resistance 
71. Stroma to parenchyma ratio in tumor could reflect patient’s 
prognosis, and a high tumor stroma percentage (TSP) was found to be associated 
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with reduced survival in colorectal cancer 
72
, breast cancer 
73
 and esophageal 
cancer
74
. Klintrup et. al. and Park et. al., validated the Klintrup–Mäkinen (KM) 
grade, a semi-quantitative evaluation for immune cells at invasive front of tumor, 
as a useful prognostic marker in colorectal cancer 
75,76
. Tumor-infiltrating 
lymphocytes were found to be associated with a favorable prognosis in gastric 
cancer with Epstein–Barr virus (EBV) infection 77. As TSP and KM grade both were 
effective in prognosis evaluation, Park et al. combined these two markers and 
provide the Glasgow microenvironment score (GMS) to increase prognostic 
utility, and its prognostic value was validated in colorectal cancer 
76
. A study from 
2017, showed that GMS in gastric cancer was a useful prognostic factor, with a low 
GMS as a manifestation of better prognosis and an inflammatory tumor 
microenvironment 
65
.  
There is increasing evidence that host inflammatory response plays an 
important role in the development and progression of cancer, in particular, by an 
elevation of C-reactive protein (CRP) levels in serum, that is a key factor in the 
progression of a variety of common solid tumors 
78
 and represents a prognostic 
marker in gastro-esophageal 
79,80
, urinary bladder 
81
, pancreatic 
82
, renal 
83,84
, and 
non–small-cell lung 85 cancers, independent of tumor stage 86. Also, 
hypoalbuminemia has been reported to be associated with poor survival in 
advanced cancers 
87,88
. McMillan described the combination of these two biomarkers 
as Glasgow Prognostic Score (GPS), that associated with tumor stage, as part of 
the assessment of the patient with cancer, will highlight the need not only to treat 
the tumor, but also the systemic inflammatory response 
86
. 
The standard imaging modalities used for the preoperative staging of gastric 
cancer include computed tomography (CT) and endoscopic ultrasonography (US). 
Endoscopic US is regarded as the most accurate imaging tool for evaluating tumor 
depth, and CT is the principal imaging modality used for staging because of its 
ability to detect distant metastases. Magnetic resonance imaging (MRI) and 
diagnostic laparoscopy are other imaging tools that can be successfully used to 
stage gastric cancer 
89
. 
Since the different biological behavior between intestinal type and diffuse 
type, researchers were concentrated in the epigenetic regulation and prognostic 
biomarkers between these two categories. Currently, a clinically molecular marker 
for GC is genomic amplification and overexpression of HER2, that occurs in around 
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15% of patients with GC, with the proportion of 33% in intestinal type and 6% in 
diffuse type 
26,32,60
. The prognostic value of HER2 positivity in advanced GC is still a 
controversial issue. Some studies indicated that HER2 amplification is associated 
with a poor prognosis and aggressive disease 
90-93
, while others showed no 
difference in prognosis when comparing with HER2 positive and negative tumors 
94-96
. Qui and colleagues suggested that the combination of Laurén classification 
and HER2 status is a better prognostic factor in gastric cancer patients. HER2 
negative intestinal type gastric cancer patients presented a better survival 
comparing to HER2 positive diffuse type gastric cancer patients 
97
. Investigations 
of biological biomarkers and genetic therapeutic targets should be continuous in 
gastric cancer treatment 
98
.  
Table 3 - T-staging of gastric cancer. 
TX Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
Tis 
Carcinoma in situ: intraepithelial tumor without invasion of the lamina 
propria 
T1 Tumor invades the lamina propria, muscularis mucosae, or submucosa 
T1a Tumor invades the lamina propria or muscularis mucosae 
T1b Tumor invades the submucosa 
T2 Tumor invades the muscularis propria 
T3 
Tumor penetrates the subserosal connective tissue without invasion of 
the visceral peritoneum or adjacent structures. T3 tumors also include 
those extending into the gastrocolic or gastrohepatic ligaments or into 
the greater or lesser omentum, without perforation of the visceral 
peritoneum covering these structures 
T4 Tumor invades the serosa (visceral peritoneum) or adjacent structures 
T4a Tumor invades the serosa (visceral peritoneum) 
T4b 
Tumor invades adjacent structures, such as the spleen, transverse 
colon, liver, diaphragm, pancreas, abdominal wall, adrenal gland, 
kidney, small intestine, and retroperitoneum 
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3. Diabetes and gastric cancer 
Cancer and DM are very common diseases that have heterogeneous 
developmental pathways. Increasing incidence trends of both these diseases may 
at least partly be due to the shared risk factors and mechanistic pathways 
99
. Shared 
risk factors include both non-modifiable (age, gender and race) and modifiable risk 
factors (obesity, diet and smoking). Experimental and epidemiological evidence 
indicates that DM is associated with several types of cancer 
20
, including gastric 
100,101
, breast 
102-104
, ovarian 
105
, liver 
106,107
, pancreas 
108-112
, esophageal 
113
, colorectal 
114-
117
, endometrial 
118,119
, kidney 
120,121
, non-Hodgkin lymphoma 
122,123
 and urinary bladder 
124
.  
Shared risk factors, such as obesity 
125-127
, hyperinsulinemia 
128,129
, diet and 
smoking 
130-132
, hyperglycemia 
133,134
, H. pylori infection 
130,131,135
, salt intake 
130,136
, 
and medications 
130,137
, may be the possible link between diabetes and cancer.  
DM2 is characterized by metabolic changes in the body (hyperglycemia, 
dyslipidemia, insulin resistance), which associates with pathological processes 
such as chronic inflammation, oxidative stress, angiogenic imbalances and tissue 
fibrosis that could be some of the shared mechanistic processes between DM and 
GC 
101,138-140
. Hyperinsulinemia, between these factors, is considered to be the 
primary mechanism of shared risk of DM and cancer. Insulin has been shown to 
have both metabolic and mitogenic capabilities. Hyperinsulinemia, either through 
insulin resistance or through insulin-like growth factor (IGF) 1 system, may result 
in up-regulation of the mitogenic and anti-apoptotic effect, thus mediating the 
cancer initiation and progression 
138
. Hyperglycemia, on the other hand, has been 
shown to support carcinogenesis indirectly by increasing insulin production and by 
providing glucose for energy metabolism of cancer cells. Obesity has also been 
shown to indirectly increase the risk of cancers due to increased hyperglycemia, 
insulin resistance and inflammation 
101
. Most of these shared factors and 
mechanisms are not site specific and would be common to many cancer sites. If 
the association between DM and cancer is only because of these common factors, 
the increased risk should be consistent across most anatomical sites 
131
.  
  
Página | 15 
 
3.1. Shared risk factors 
Obesity is often linked with glucose intolerance, insulin resistance and 
dyslipidemia 
141
. Serum insulin and IGF-1 are thus higher in obese people as 
compared to healthy lean individuals, and have been reported to increase the risk 
of some types of cancer 
142
. In fact, patients with cancer that have pre-existing DM2 
have worse prognosis and have higher mortality rates than ones who had a normal 
glycemic values 
143
.  The mechanisms by which these molecules affect cancer are 
yet undetermined. However, a cross talk between these and PI3K/mTOR and Ras 
signaling pathways, two transduction pathways often implicated in cancer cells, 
was established 
144
, explaining their effects in inhibiting apoptosis, and stimulating 
tumor proliferation 
145
. The fact that insulin and IGF-1 are overexpressed in obesity, 
leads us to assume that obese patients are much more predisposed to develop 
more aggressive tumors than lean subjects. 
Hyperinsulinemia, especially when patients had insulin resistance, is one 
more possible mechanism of gastric carcinogenesis in DM 
146-148
. Since insulin has a 
mitogenic effect, it is tempting to speculate that hyperinsulinemia may be involved 
in gastric mucosal proliferation where genetic alterations are inducible. Increased 
insulin levels will activate mitogenic pathways through its binding to its receptor 
(IR) and to insulin and IGF-1 hybrid receptors (IR/IGF-1R). The binding of the 
hormone to these receptors in cancer cells will eventually activate MAPK and the 
PI3K/Akt oncogenic pathway 
149
. Moreover, hyperinsulinemia may also have an 
indirect effect in the development of cancer, by increasing IGF-1, an important 
growth factor in cancer, which role is regulating the cellular growth and the survival 
of transformed cells 
150
 and decreasing IGF binding proteins (IGFBs). In fact, it is 
thought that the mitogenic effects of insulin are mediated by IGF-1, since it's the 
activation of IGF-1R that stimulates cell growth and proliferation. 
Smoking is another risk factor for DM 
151
 and GC 
152
. Because of the higher 
risk of gastric cancer associated with diabetes is still significant after adjustment 
for smoking. The link between these diseases can also be independent of smoking 
133,134
.  
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3.2. Hyperglycemia 
Hyperglycemia may also promote carcinogenesis via increasing reactive 
oxygen species resulting in DNA damage 
153
 or increasing the expression of 
vascular endothelial growth factor, which is correlated with tumor vascularity and 
metastasis 
154
. The VEGF/VEGFR system is also been showed to interact with the 
IGF/IGF-IR axis in various tumors including gastrointestinal ones 
155,156
. As cancer 
cells have lesser capacity in using glucose for energy expenditure, and they may 
consume more glucose than normal cells (the Warburg effect), hyperglycemia 
provides a more suitable condition for tumor cells to grow 
157
.  
Some studies, in vivo and in vitro, support the association between 
hyperglycemia and gastric cancer, possible via β-catenin acetylation with increased 
Wnt signaling 
158
, which is also characteristic of gastric cancer 
159
. Expression of pro-
inflammatory cytokine such as interleukin-1, interleukin-6 and tumor necrosis 
factor-α had an increased expression in DM patients 160. It is also shown that these 
factors may upregulate and activate the Wnt/β-catenin pathway 161.  
Additionally, an interaction between hyperglycemia and H. pylori infection 
was reported to markedly increase the risk of gastric cancer 
21
.  
3.3. H. pylori infection 
H. pylori infection is well known as a risk factor for gastric ulcer and cancer 
152,162,163
. H. pylori may increase the risk of GC either directly through mutagenic or 
protein modulatory effect on the epithelium or indirectly by induction of 
inflammatory process in the epithelium 
164-166
. However, not all individuals infected 
with H. pylori develop GC, suggesting the requirement of other cofactors to aid H. 
pylori mediated carcinogenic process. Patients with diabetes may have a higher 
infection rate, a lower eradication rate, and/or a higher reinfection rate of H. pylori 
167-169
. H. pylori, through gastrin secretion, can increase the glucose-stimulated 
insulin release, thereby resulting in hyperinsulinemia 
170
. It has also been shown 
that H. pylori independently promotes insulin resistance and related oxidative 
stress, thereby also possibly facilitating the hyperinsulinemia-mediated 
carcinogenic process in the gastric mucosa 
171,172
 Insulin resistance, induced by H. 
pylori infection, may also accelerate -cell loss and lead to diabetes. Therefore, 
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insulin deficiency, as well as insulin resistance, might be seen in chronic H. pylori 
infection 
173,174
. 
On the other hand, the active chronic inflammation induced by H. pylori 
infection may also increase the risk of DM2, because it may affect the normal 
secretion and function of insulin leading to glucose dysregulation 
171,173,175
. 
3.4. Salt intake 
Evidence has been provided some strong associations between gastric 
cancer and a few dietary factors, among which is the dietary salt content and the 
habitual consumption of salt-rich foods 
176
. Many case-control studies detected an 
adverse effect of high salt consumption on the risk of gastric cancer 
177
.  
A recent meta-analysis of these studies has shown that dietary salt intake is 
directly associated with the risk of gastric cancer, with progressively increasing risk 
across increasing levels of habitual consumption 
178
. This epidemiological evidence 
is supported by the results of clinical and experimental studies which found that 
high salt intake may alter the viscosity of the gastric protective mucous barrier 
179
 
and increase the colonization by Helicobacter pylori , a recognized risk factor for 
gastric cancer 
180
. High intra-gastric sodium concentrations were shown to cause 
mucosal damage and inflammation, which in turn has been reported to increase 
cell proliferation and endogenous mutations 
181,182
. 
3.5. Anti-diabetic drugs and cancer  
The function of the major classes of DM drugs is replace the circulating 
insulin and reduce hyperglycemia by different mechanisms 
183
. Agents which treat 
or prevent DM2 might be expected to influence risk of cancer favorably. The insulin 
sensitizers, metformin, and thiazolidinediones (TZDs) are promising cancer 
therapies 
139
. 
In particular, metformin, the drug of choice for the management of DM2 
184
, 
reduces levels of both circulating glucose and insulin in patients with insulin 
resistance and hyperinsulinemia, by altering signaling through the AKT/mTOR 
pathway 
185,186
. The mechanisms for the anti-tumor effects of metformin include an 
inhibition of cell proliferation, decrease cancer proliferation, with partial cell-cycle 
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arrest in oncogenic cell lines with the activation of 5’ adenosine monophosphate-
activated protein (AMP) and AMP-kinase (AMPK) 
101
. AMPK is an essential mediator 
of the tumor suppressor LKB1. Because of its properties, AMPK could be used to 
suppress cancer cells containing loss-of-function LKB1 mutations, active B-Raf 
mutations, or in cancers associated with metabolic syndrome 
139
. 
Thiazolidinediones, bind to peroxisome proliferator-activated receptor 
(PPAR) gamma (γ) receptor molecules inside the cell nucleus which, when activated, 
result in transcription of a variety of genes. PPAR γ is an adipocyte transcription 
factor, stimulating differentiation of adipocytes as well as inhibiting inflammatory 
cytokine production 
187
. This class of drugs reduces insulin levels by enhancing 
insulin action. PPAR-γ activation results in reduced free fatty acids and eicosanoids 
and inhibition of VEGF-induced angiogenesis, amongst other actions 
188
. Like 
metformin, TZDs inhibit cancer cell growth, potentiation, and proliferation, 
inducing apoptosis, at the in vitro level 
101,189
.  
However, some studies duggest that anti-diabetic drugs may also have 
effects on the risk for cancer. Some studies shows that insulin sensitizers such as 
metformin and TZDs are associated with prostate cancer 
190
 and HER2-positive 
breast cancer 
191
 among diabetic patients. Nonetheless, it is more expected that 
diabetic patients, who are treated with insulin or insulin secretors, develop cancer 
than those with metformin 
192-195
. 
 
3.6. Biological links between diabetes and gastric cancer 
Chronic inflammation, angiogenesis, fibrosis and oxidative stress are also 
considered to be some of the shared mechanistic processes between diabetes and 
cancer, via their influence on neoplastic processes 
99,196
. 
Clinical studies also showed an increased risk of diabetes being associated 
with different types of cancers 
197
. In diabetic patients with a deregulated glucose 
metabolism, were usually found increased levels of chronic inflammatory markers, 
e.g., interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α, and emerging 
evidence has highlighted activation of the immune response in the progression and 
development of cancer cells. Consequently, uncontrolled proinflammatory 
responses could possibly create a chronic inflammatory state, promoting a 
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satisfactory microenvironment for tumor and potentially promoting immune over-
activation and cancer growth 
15
.  
Chronic inflammatory condition associated with diabetes, which usually 
persists for years to decades, may increase inflammation-caused ROS by reducing 
intracellular antioxidant activities 
198
. Oxidative stress, has long been recognized as 
an adverse event for promoting tumorigenesis and cancer progression 
199,200
. 
Exacerbated levels of ROS can irreversibly modify protein, lipid and DNA molecules, 
and permanently or temporarily change their cellular behavior, leading to the 
accumulation of somatic DNA mutations, proto-oncogenes activation and 
epigenetic alterations. Conversely, increased signaling via AKT, RAS\RAF\ERK and 
NF-κB pathways, constitutively activated signaling cascades in most malignant cells, 
stimulate endogenous ROS production, further enhancing oxidative damages 
within the tumor microenvironment 
201,202
. Furthermore, various types of cells 
present in the tumor microenvironment can generate not only ROS but also reactive 
nitrogen species (RNS). Tumor associated macrophages are effective producers of 
ROS and RNS and further contribute to a pro-oxidant environment 
203
. Another 
potential mechanism is related to a proinflammatory and pro-tumorigenic cytokine 
- TNF-α -, produced by adipose tissues 204, that plays a significant role in cancer 
formation and cancer development by upregulating the transcription factor, NF-кB 
205
. NF-кB is known to be involved in the association between cancer and 
inflammation, by manipulating cytokine production and even the angiogenesis 
potential in immune-responsive cells.  
Studies which showed the correlation between chronic inflammation and 
hyperglycemia 
206
 portray possible mechanisms at the intersection of obesity, 
hyperglycemia, diabetes, chronic inflammation, and cancer development. Over-
activated proinflammatory cytokines continuously drive cell survival and induce a 
proinflammatory response, which could conceivably create a chronic inflammatory 
state, resulting in a pro-tumor microenvironment. 
Angiogenesis is a global term associated with the physiological process 
involving the growth of new blood vessels or neovascularization. Angiogenesis is 
an important step in the transition of tumors from a confined local to malignancy 
207
. Neovascularization or angiogenesis has also been interchangeably associated 
with vasculogenesis which primarily refers to developmental formation of vascular 
structures from circulating or tissue-resident endothelial progenitor cells that 
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proliferate into de novo endothelial cells. Angiogenesis predominantly relates to 
formation of endothelium-lined microvasculature with supportive cells. These 
processes require several biochemical and physiological factors to stimulate vessel 
sprouting and remodeling of the primitive vascular network, which in turn establish 
stable and functional blood vessel networks. There are several angiogenic factors 
which are involved in stimulation, promotion, and stabilization of new blood 
vessels such as the family of vascular endothelial growth factors (VEGFs) which 
comprises VEGF-A, VEGF-B, VEGF-C, VEGF-D and placental growth factor (PlGF) 
208
.  
VEGF-A is the most potent angiogenic factor of VEGF family, and exerts its 
action through the activation of its main receptor, VEGFR-2 and target proteins 
promoting vascularization 
209,210
. Hypoxia, inflammation and oxidative stress, are 
among the principal angiogenic stimuli presented in both diabetes and cancer. In 
response to angiogenic stimuli, endothelial cells (EC) proliferate and migrate to 
avascular areas. In this situation, EC at the front of migrating vessel rely on 
glycolysis to produce ATP for rapid generation of energy and sprout 
211
. The EC 
glucose uptake is mediated through the activation of the PI3K-AKT pathway, 
promoting the expression of glucose transporters, mainly GLUT-1 
212
. It has been 
reported that the 6- phosphofructo-2-kinase-2/fructose-2,6-bisphosphatase 3 
(PFKFB3) enzyme expression is induced by hypoxia in avascular areas in several cell 
lines 
213
 and human cancer cell 
214
. PFKFB3 is a bifunctional enzyme abundant in EC, 
that plays an important role in ensuring the high glycolytic flux, essential for vessel 
growth
211
.  
Recently, Schoors and collaborators demonstrated the therapeutic potential 
of endothelial PFKFB3 regulation by inhibiting PFKFB3 in vitro and silencing PFKFB3 
in vivo and the resultant effect was a 30-40% decrease in the glycolytic pathway 
sufficient to reduce angiogenesis 
215
. These data suggest that anti-angiogenic 
therapies could be based on the inhibition of this metabolic target, starving 
pathological vessels. Thus, PFKFB3 expression emerges as an important regulator 
of the endothelial phenotype, postulating that a metabolic switch induces the 
angiogenic switch and could be an important strategy to counteract the increased 
tumour vascularization. 
Fibrotic tumour microenvironment is associated to poor prognostic, 
influencing tumour progression and invasion, and hampering the efficacy of 
chemotherapy 
216-218
. Different cell types contribute to the fibrosis stage tumour 
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microenvironment, including fibroblasts, leucocytes such as neutrophils, 
lymphocytes and macrophages, and adipocytes 
219
. In a fibrotic tumor stroma, the 
abnormal deposition of collagen and impairment in degradation of these proteins 
leads to decrease in flexibility and increased stiffness and density of ECM, which 
lead to changes mechanical forces and in cellular signaling, facilitating survival and 
migration of the cancer cells 
217,220
.  
Angiogenesis imbalance, chronic Inflammation, oxidative stress, that are 
some of the putative biological links between DM2 and GC, could be the key of the 
development of new therapeutics against DM2 and GC.  
 
 
 
Figure 2 - Interrelationship between pathological mechanisms and modifiable and non-modifiable risk 
factors involved in diabetes, obesity and cancer. IGF, insulin-like growth factor. 
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The main aim of this thesis was to investigate the mechanisms that may 
justify the association of DM2 and GC, and possibly helps us identify a sub-group 
of GC patients that is highly associated with DM2, and may in the future, beneficiate 
from more metabolic focused therapies.  
Taking advantage of the hospital tumor bank, we will identify inflammatory 
and angiogenic pathways, often imbalanced in diabetic subjects, that are 
differentially expressed in GC patients with DM2. 
Investigate the role of a new prognostic score associated to diabetes and 
gastric cancer patients. 
  
 
 
  
 
  
 
 
 
Material and Methods 
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1. Study design  
 
Approval for this study was obtained from the Ethical Committee of Centro 
Hospitalar São João, Porto, Portugal.  
This study included 43 individuals diagnosed with gastric cancer. The 
diagnosis was confirmed pathologically, after the histopathological examination of 
either the tissue or the endoscopic biopsy. Of these, 22 patients had DM2 clinically 
diagnosed by an endocrinologist and were on at least one antidiabetic oral drug 
(metformin). All the patients with a confirmed gastric adenocarcinoma and DM2 
were included in the study. Gastric tissues of each patients were obtained from 
Tumor Bank of Centro Hospitalar São João, Porto, Portugal.  
A retrospective review of our gastric surgical database from July 2008 to 
September 2014 was performed. Pathological and clinical data from our patients 
were collected.  
Two groups were established, one group of patients with only gastric cancer 
(control group), and other group with gastric cancer and DM2 (diabetic group). 
Each patient was extensively characterized regarding both the tumor 
pathological features and the available clinical data. Inclusion criteria for both 
groups were not insulin-dependent, did not present any other previous neoplasia, 
did not receive neoadjuvant chemotherapy, radiotherapy, or both. For diabetic 
group, additional criteria were only the clinical diagnostic DM2 and prescribed anti-
diabetic medication but not have more than two anti-diabetic drugs, 
simultaneously.  
All patient’s glycaemias at the moment of surgery and at random time-points 
were checked to make sure the metabolic state of the patients was accurate. This 
approach was used to assure that the key difference between groups was the 
presence or absence of diabetes. 
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2. Histology review 
Full sections of 43 cases of gastric cancer were stained with hematoxylin & 
eosin (HE) and were scanned in a microscope (Nikon Eclipse 50i, Germany) by a 
pathologist specialized in gastric cancer.  Tumor Stroma Percentage (TSP) was then 
semi-quantitatively assessed according to the criteria previously reported by Park 
et al. 
76
. Briefly, the TSP evaluation was performed by using the most invasive tumor 
area. Thereafter, TSP was calculated as the percentage of stroma relative to the 
whole tumor area, and tumors were subgrouped as high TSP (>50%) or low TSP 
(≤50%). A score 0 was defined as low TSP and score 1 as a high TSP.  
For each case, the Klintrup–Mäkinen (KM) grade was evaluated as previously 
described by Klintrup et al. 
75
 and Park et al. 
76
. Briefly, overall inflammatory reaction 
at the invasive margin was scored as:  
- 0, no increase of inflammatory cells;  
- 1, mild and patchy aggregation of inflammatory cells;  
- 2, markedly increased inflammatory cells at the invasive margin formed 
a band, and some cancer cells might be destructed by inflammatory cells;  
- 3, very prominent inflammatory cell infiltration formed a florid-like zone, 
and destructed cancer cell could be observed invariably. 
A score of 0 or 1 was defined as low KM grade, while a score of 2 or 3 was 
high KM grade. Then, a score 0 was define as low KM and a score 1 as high KM.  
In the present study, all cases of gastric cancer were reviewed in a double-
blinded fashion by a pathologist with subspecialty training and experience in 
gastric pathology. 
2.1. Assessment of Glasgow Microenvironment Score 
The GMS was a combination of the TSP and KM grade, as described 
previously by Park et al.:  0 score, a high KM grade with high or low TSP; 1 score, 
low TSP with low KM grade; 2 score, high TSP with low KM grade. According to GMS, 
the 43 cases were stratified into three subgroups. 
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3. Assessment of GPS 
All values of C-reactive protein and albumin were collected and grouped as 
previously described by 
221
. 
The resultant prognostic score (0, 1, 2) was defined as follows:  
- Patients with both an elevated C-reactive protein (>10 mg/l) and 
hypoalbuminemia (<35 g/l) were allocated a score 2; 
- Patients in whom only one of these biochemical abnormalities was 
present were allocated of 1; 
- Patients in whom neither of these abnormalities was present allocated a 
score 0. 
4. Fibrosis evaluation 
To label collagen components within cancer tissues, the tissue sections were 
stained with 0.5% Sirius Red (Direct Red 80; Sigma-Aldrich). Then the slides were 
observed and images were taken using Nikon Eclipse 50i microscopy. Thereafter, 
images of each tissue core were thresholded with ImageJ (version 1.48v, NIH, 
Bethesda USA), and pixel densities of collagen components were detected. 
 
5. Microvessel density evaluation 
5.1. Immunohistochemistry  
CD31 has cytoplasmic, membranous expression in non-neoplastic and 
neoplastic vascular endothelial cells 
222
. It has been used as a tool to identify the 
vascular origin of neoplasms such as angiosarcomas, Kaposi sarcomas and 
epithelioid hemangioendothelioma 
222,223
.  Immunohistochemical study against 
CD31 has also been shown useful to detect areas of tumor lymphovascular invasion 
224
. Additionally, detection of weak diffuse cytoplasmic CD31 immunoreactivity has 
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been seen in cases of various carcinomas with occasional membranous staining in 
ductal carcinomas of the breast as well as in intratumoral macrophages 
225,226
 
The gastric tissue sections were processed on an automatic staining 
equipment BenchMark ULTRA System (Ventana Medical Systems) using the mouse 
monoclonal antibody, anti-CD31 (Cell Marque (JC70)). Each slide was individually 
processed, starting by heating the blades to 72°C, followed by deparaffinized with 
the EZprep (Ventana) buffer solution. For antigen-retrieved was used the Cell 
Conditional 1 (CC1) buffer solution, consisting of Tris/Borate and 
Ethylenediaminetetraacetic acid (EDTA), pH 8.4, 24 minutes at 100°C. Inhibition of 
endogenous peroxidase was carried out with a commercial solution of 0.04% 
hydrogen peroxide (H2O2) in phosphate-buffer solution (Ventana). Thereafter, the 
tissue sections were incubated with the primary antibody for 44 minutes at 37°C. 
Subsequently, washes were performed with the reaction buffer (Ventana), a wash 
buffer solution, pH 7.6, used for the washes between the various processing steps. 
The tissue sections were then incubated with the detection kit OptiView Universal 
Diaminobenzidine Tetrahydrochloride (DAB) (Ventana). The OptiView Universal DAB 
(Ventana) use a set of synthetic molecules, to detect the antigen-antibody 
interaction. This system consists of 6 reagents: OptiView peroxidase inhibitor, 
OptiView HQ universal linker, OptiView HRP multimer, OptiView H2O2 and OptiView 
Copper. The kit uses first the OptiView HQ universal linker, a cocktail of secondary 
antibodies (anti-rat and anti-rabbit), which binds to the primary antibody previously 
linked to the antigen. The HRP multimer OptiView, a tertiary antibody, also referred 
to as multimer, is then conjugated to an HRP peroxidase enzyme which recognizes 
the secondary antibody. HRP enzymes conjugated to the multimer react with the 
hydrogen peroxide substrate (OptiView H2O2), and with OptiView Copper, oxidize 
the OptiView DAB chromogen, giving rise to a brown precipitate. Subsequently, the 
tissue sections were contrasted with Hematoxylin for 8 minutes and Bluing Reagent 
(Ventana, Roche) for 4 minutes. Bluing reagent is an alkaline solution that enhances 
the nuclear contrast, making the nuclei more bluish. 
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5.2. Immunohistochemistry Scoring  
The number of vessels was counted in three photos for each of three 
hotspots of vessels in tumor and adjacent area of the tissue sections for each 
patient. A negative control was included. Any positive-stained EC or cluster that 
was separated from adjacent vessels was considered an individual vessel.  
 
6. Statistical analysis 
Qualitative variables were expressed as number of cases and percentage (%), 
and the quantitative variables are expressed as mean and standard error of the 
mean. The D'Agostino-Pearson test was used to verify the normality of the data.  
The difference between two independent experimental groups was 
evaluated using the unpaired Student t test for normally distributed variables, and 
the Mann-Whitney U test for variables that did not meet the normal parameters.  
To compare 3 or more independent groups with normal distribution we used 
a simple analysis of variance (one-way ANOVA) with post-hoc Tukey’s test. Kruskal-
Wallis ANOVA with Dunns post hoc was used to compare 3 or more groups when a 
sample did not meet the criteria of normality.  
To compare 2 or more nominal variables, we used a chi-square test. To 
evaluate whether diabetes status (yes versus no) might be associated with gastric 
cancer survival at 2 and 5 years, odds ratios and their 95% confidence intervals 
were calculated. We performed Kaplan-Meier (K-M) analysis to test if diabetic status, 
GPS and GMS were significant for prognosis or prediction for 2 and 5-year survival. 
 A p value <0.05 was considered statistically significant and <0.01 very 
significant. All statistical analyses were performed with the aid of the GraphPad 
Prism software version 7.00 and IBM SPSS Statistics version 24, both for Windows. 
 
 
  
 
 
 
 
Results 
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1. Cohort characteristics  
In the studied cohort, patients were paired by their demographic and 
clinicopathologic features, except on diabetic parameters’ such as blood glucose 
(Figure 3) and diabetic specific medication. 
 
 
 
 
 
 
 
 
Figure 3 - Blood glucose at the surgery. Data represents mean ± SE. *** p < 0.01. 
 
Patients characteristics are shown in Table 4. 
In the control group, 66.7% had more than 70 years and 66.7% was female. 
Of the 21 patients, 52.4% had intestinal type of gastric cancer. 4.8% had diffuse 
type, 33,3% had mixed type and 9.5% had indeterminate type. The lower part of the 
stomach was the most affected in this group (71.4%), and 71.4% of tumors was 
bigger than 5 cm. Only 3 (14.3%) of the 21 patients had recurrence of the disease.   
In diabetic group, 81.8% had more than 70 years and 68.2% was female. Of 
the 22 patients, 40.9% had intestinal type of gastric cancer, 4.5% had diffuse type, 
27.3% had mixed type and 27.3% had indeterminate type. The lower part of the 
stomach was also the most affected in this group (68.2%). 31.8% of the diabetic 
patients had recurrence of the disease.  
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Table 4 – Demographic and clinicopathological characteristics of the studied cohort (n=43). 
 
 
 
  
Group  
Control Diabetic 
p 
N % N % 
Gender Female 14 66.7% 15 68.2% 
ns 
Male 7 33.3% 7 31.8% 
Age <70 7 33.3% 4 18.2% 
ns 
>70 14 66.7% 18 81.8% 
Laurén Intestinal 11 52.4% 9 40.9% 
ns 
Diffuse 1 4.8% 1 4.5% 
Mixed 7 33.3% 6 27.3% 
Indeterminate 2 9.5% 6 27.3% 
pT stage T1 1 4.8% 2 9.1% 
ns 
T2 2 9.5% 2 9.1% 
T3 13 61.9% 12 54.5% 
T4 5 23.8% 6 27.3% 
pN stage N0 6 28.6% 10 45.5% 
ns 
N1 3 14.3% 4 18.2% 
N2 4 19.0% 3 13.6% 
N3 8 38.1% 5 22.7% 
M stage Mx 20 95.2% 18 81.8% 
ns 
M1 1 4.8% 4 18.2% 
Stage I 2 9.5% 3 13.6% 
ns II 6 28.6% 9 40.9% 
III 13 61.9% 10 45.5% 
Lymphatic 
invasion 
No 5 23.8% 5 22.7% 
ns 
Yes 16 76.2% 17 77.3% 
Vascular 
invasion  
No 7 33.3% 9 40.9% 
ns 
Yes 14 66.7% 13 59.1% 
Neural invasion No 8 38.1% 8 36.4% 
ns 
Yes 13 61.9% 14 63.6% 
Location Upper 2 9.5% 1 4.5% 
ns 
Middle 3 14.3% 4 18.2% 
Lower 15 71.4% 15 68.2% 
Diffuse 1 4.8% 2 9.1% 
Size <5 cm 6 28.6% 7 31.8% 
ns 
  >5 cm 15 71.4% 15 68.2% 
R state R0 18 85.7% 20 90.9% 
ns R1 3 14.3% 1 4.5% 
R2 0 0.0% 1 4.5% 
Recurrence No 18 85.7% 15 68.2% 
ns 
Yes 3 14.3% 7 31.8% 
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2. Significance of DM2 for GMS, GPS and 
outcome of GC 
There is increasing evidence that systemic inflammation and inflammatory 
processes in the tumor microenvironment play an important role in the 
development of several tumors 
227,228
. In brief, in this study we investigated the 
prognostic relevance of GMS, GPS and evaluated the patients’ outcome. 
2.1. DM2 and GMS 
GMS was a combination of KM and TSP markers, such as described in 
Material and Methods chapter.  
The scoring of TSP and KM to assess the GMS score was shown in Table 5. 
In the KM score distribution between control and diabetic group appears to 
be skewed in the opposite direction, in score “0” (36.4% vs 61.9% respectively), and 
in score “1” (38.1% vs 63.6%, respectively), although the difference is not 
significant. 
In the TSP score, the distribution of diabetic patients through different 
scores, 0 and 1, was statistically different compared with control group (p=0.021). 
In control group, the distribution of patients seems to be more homogeneous 
between the TSP scores (57.1% vs 42.9%, for “0” and “1”, respectively). In diabetic 
patients, this distribution tends to score “1” compared with score “0” (77.3% vs 
22.7%, respectively).  
In the GMS score, the distribution of diabetic patients through different 
scores, 0, 1and 2, was statistically different compared with the control group 
(p=0.045). In the control group, the distribution of patients seems to be more 
homogeneous between the different scores (38.1% vs 33.3% vs 28.6%, for “0”, “1” 
and “2”, respectively). In diabetic patients, this distribution tends to score “0” 
compared with score “1” and “2” (63.6% vs 4.5% vs 31.8%, respectively).  
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Table 5 - Assessment of Glasgow Microenvironment Score of control group (n=21) and diabetic group 
(n=22).  
 Group  
 
Control Diabetic 
p 
N % N % 
KM 
0 13 61.9% 8 36.4% 
ns 
1 8 38.1% 14 63.6% 
TSP 
0 12 57.1% 5 22.7% 
0.021 
1 9 42.9% 17 77.3% 
GMS 
0 8 38.1% 14 63.6% 
0.045 1 7 33.3% 1 4.5% 
2 6 28.6% 7 31.8% 
2.2. DM2 and GPS 
To assess the GPS score we analyzed the systemic albumin and C-reactive 
protein values of each patients and results are showed in Table 6.  
The patients’ distribution by the different scores of GPS, in both groups of 
the studied cohort, seems to be similar.  
 
Table 6 - GPS scoring of control group (n=21) and diabetic group (n=22) 
 
Group  
Control Diabetic 
p 
N % N % 
GPS 
0 8 38.1% 8 36.4% 
ns 1 5 23.8% 4 18.2% 
2 8 38.1% 10 45.5% 
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2.3. DM2 and GC outcome 
DM2 does not appear to be a risk factor for patient survival at 2 and 5 years 
(Figure 4). 
 
 
 
 
 
 
Table 7 - Overall survival of the studied cohort 
Group N 
2-year 
OS (%) 
Odds ratio 
(95% CI) 
p 
5-year 
OS (%) 
Odds ratio 
(95% CI) 
p 
Control 21 57.14 1.60 
(0.48 – 5.34) 
ns 
19.05 1.06 
(0.23– 4.92) 
ns 
Diabetic 22 45.45 18.18 
 
 
 
 
 
 
 
Figure 4 – Kaplan-Meier survival curves of the studied cohort at 2 and 5-years 
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In stratification of the patients by GMS score, the difference of patients’ 
survival at 2 and 5 years, was not significant.  
 
 
 
 
 
 
 
 
 
 
 
In stratification of the patients by GPS score, the difference of patients’ 
survival at 2 and 5 years, was not significant. 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – Kaplan-Meier survival curves at 2 and 5-years, of all patients in study, stratified by GMS score. 
Control Diabetic 
Control Diabetic 
Diabetic 
Control Diabetic 
Control 
Figure 6 – Kaplan-Meier survival curves at 2 and 5-years, of all patients in study, stratified by GPS score. 
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3. Fibrotic status  
Erro! A origem da referência não foi encontrada. shows the macroscopic d
ifferences in fibrosis staining in control and diabetic patient, respectively. 
Erro! A origem da referência não foi encontrada. shows the fibrotic status o
f tumor microenvironment in control group (n=21) and diabetic group (n=22).  
The fibrotic status assessed by Sirius Red histological staining higher in 
diabetic group when compared with the control group both in normal adjacent area 
(12.288 ± 1.53 vs 10.975 ± 1.076) and in the tumor area (9.362 ± 1.337 vs 7.165 
± 1.012). 
In the control group, the tumor area was more fibrotic when compared to 
the normal adjacent area (7.165 ± 1.012 vs 10.975 ± 1.076). 
In the diabetic group, the tumor area was also more fibrotic then the normal 
adjacent area (9.362 ± 1.337 vs 12.288 ± 1.53). 
 
 
 
 
 
 
 
 
 
 
 
A B 
Figure 7 - Fibrosis staining in (A) control patient and (B) diabetic patient. 
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Figure 8 - Fibrotic status of control (n=21) and diabetic (n=22) gastric cancer groups, by Sirius Red 
staining. Control group: 7.165 ± 1.012 vs 10.975 ± 1.076.  Diabetic group: 9.362 ± 1.337 vs 12.288 
± 1.531. Data represents mean ± SE.  
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4. CD31 staining analysis   
The development of DM2 and cancer comprises distinct extracellular matrix 
remodeling and deregulated angiogenesis in different organs. We next evaluated 
whether these diseases interfere with the number of vessels in diabetic (n=22) and 
control patients (n=21), in normal adjacent area and tumor area Erro! A origem da r
eferência não foi encontrada..  
Results are shown in Erro! A origem da referência não foi encontrada..  
The microvessel density was higher in control group compared with the 
diabetic group, both in normal adjacent area (17.55 ± 2.084 vs 12.63 ± 1.029), and 
in tumor area (16.27 ± 1.463 vs 11.56 ± 0.639). 
In the control group, normal adjacent area had more density of microvessels 
when compared with tumor area (17.55 ± 2.084 vs 16.27 ± 1.463). 
In the diabetic group, normal adjacent area had higher density of 
microvessels when compared to the tumor area (12.63 ± 1.029 vs 11.56 ± 0.639).  
 
 
 
 
Figure 9 - Microvessel staining: microvessel were highlighted by staining endothelial cells (staining 
against CD31 antibody). (A) – Normal adjacent area of control patient. OM: 200x. (A1) OM: 400x; (B)) 
tumor area of control patient. OM: 200x. (B1) OM: 400x; (C) Normal adjacent area of diabetic patient. 
OM: 200x. (C1) OM: 400x; (D) tumor area of diabetic patient. OM: 200x. (D1) OM 400x. 
A B 
C D 
A1 B1 
C1 D1 
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Figure 10 - Gastric cancer microvessel density of control (n=21) and diabetic group (n=22) assessed 
by CD31 staining. Control group: 17.55 ± 2.084 vs 16.27 ± 1.463. Diabetic group: 12.63 ± 1.029 vs 
11.56 ± 0.639. Data represents mean ± SE.  
  
 
 
 
 
Discussion  
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With the industrialization of the modern World, diseases such as obesity and 
its co-related comorbidities such as DM2 have increased its prevalence 
dramatically. The overall influence of these metabolically associated pathologies in 
the development and progression of multiple malignancies have been under the 
scope of researchers for a long time. It is becoming increasing evident that there 
is a substantial increase in cancer incidence in diabetic patients
130
. However, the 
mechanisms by which this association occurs it is not fully understood.  There are 
lots of biopathological factors that may play an important role in the process of 
cancer initiation and progression and that are also present in diabetes, such as 
angiogenesis imbalance, chronic inflammation and oxidative stress, among 
others
99
. 
Various malignancies have been associated with metabolic disturbances, 
and one of these is gastric cancer 
99
. In many studies, it has been suggested that, 
not only, does metabolic disease appear to promote the development of cancer but 
it also appears to be associated with a worst prognosis.  
The main aim of this thesis was to investigate the mechanisms that may 
justify the association of DM2 and gastric cancer and possibly helps us identify a 
sub-group of gastric cancer patients that is highly associated with DM2, and may, 
in the future, beneficiate from more metabolic focused therapies. Taking advantage 
of the collaboration of the Unit of Biochemistry, of the Department of Biomedicine 
of the Faculty of Medicine of the University of Porto, with the tumor bank of the 
Centro Hospitalar São João, Porto, Portugal, we gained access to formalin-fixed, 
paraffin embedded tissue samples, and also had access to several clinical and 
pathological information associated with each patient.  
We started by establishing two experimental groups from the lists of 
available samples: a group of patients with gastric cancer that have DM2 (n=22) 
and a control group with patients with gastric cancer but no known metabolic 
disease (n=21). In brief, to avoid confounding variables, the diabetic group was 
initially defined and only patients who were not insulin-dependent, did not present 
any other previous neoplasia, did not receive neoadjuvant chemotherapy or 
radiotherapy, or both, and were not on more than 2 anti-diabetic drugs 
simultaneously were included. In order to establish the control group, patients who 
had similar clinical and pathological parameters were chosen. Although all diabetic 
patients were taking at least one anti-diabetic drug, the glycaemia in the moment 
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of surgery and from random time-points were checked to make sure the metabolic 
state of the patients was accurate. This approach was used as to assure that the 
key difference between groups was the presence or absence of DM2. The available 
clinical and pathological data of the patients was collected to better characterize 
the patients. Unfortunately, we were not able to fully characterize the metabolic 
landscape of the patients, as several values regarding body weight, height (which 
would allow us to calculate the BMI), Hba1c, insulin, lipid metabolism, among 
others were missing from the clinical record we had access to, as the patients may 
have been followed in private practice.  
Although the diabetic patients were clinically diagnosed beforehand, and all 
of them were on anti-diabetic drugs, their glycaemias was not totally under control. 
At the moment of surgery, the diabetic group presents a significantly higher blood 
glucose levels when compared to the control group (190.1  13.6 mg/dL vs 98.2  
3.6 mg/dL, p<0.001, respectively). As there were very few values of HbA1c 
available, we cannot infer about the glycemic status of the patients. An insufficient 
control of the diabetic status may not be enough to avoid diabetic associated 
complications. 
Paraffin embedded tumor samples were used to evaluate fibrosis and 
vascular density. We have performed and quantified the Sirius red stained area to 
access fibrosis, and have performed an anti-CD31 immunohistochemistry to access 
the microvascular density in both groups. An experienced pathologist evaluated 
both the Klintrup-Mäkinen (KM) grade, a semi-quantitative evaluation for immune 
cells, and the tumor stroma percentage (TSP), which allowed us to access the 
Glasgow Microenvironment Score (GMS).  Also, a modified Glasgow Prognostic 
Score was calculated, based on hematological components, to give a systemic 
inflammation-prognostic score. 
It is described in the literature that the incidence of gastric cancer is higher 
in male than in female patients 
131
. However, in the cohort that was available to our 
study, and that fulfilled our inclusion criteria, were more women than men (Table 
4), which was a consequence of the availability of information regarding the 
possible patient. There were no significant differences between the mean age of 
the patients at the time of the diagnostics.  
Focusing on the pathological parameters, the histological type, the T-state, 
the stage and the localization of the tumors are very similar between the 
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experimental groups (Table 4). In our cohort, as it is described in the literature, the 
intestinal type of gastric tumor was the most frequent 
27
. However, when focusing 
on the localization of the tumor, the current worldwide trends in gastric cancer 
indicate that gastric cardia tumors are increasing 
49
, probably due to an increase in 
obesity and metabolic disturbances. These tumors are highly associated with 
gastroesophageal reflux which is a known consequence of obesity. Nonetheless, in 
Portugal and Asia, the most frequent tumors are the ones in the lower part of the 
stomach, which is reflected in our cohort 
28,29
. These tumors are more associated 
with H. Pylori infection. Our cohort corroborates the data available in the literature 
that states that gastric cancer is often diagnosed late, as it early stages do not 
present clinical symptoms, and were diagnosed in an advanced stage 
33
. 
Recently, a paper was published by Zhou, et al, that aimed to evaluate the 
prognostic value of the Glasgow Microenvironment Score in gastric cancer 
65
. The 
authors indicate that a lower GMS value was associated with a better prognostic.  
Guided by this paper, an experienced pathologist evaluated the inflammatory 
status, given by the KM score and the tumor stoma percentage. These scores were 
used to further assess the GMS of our cases. We found that the diabetic and control 
patients have significantly different distribution profiles according to the GMS 
value. Our diabetic group presented, more frequently, a lower value for GMS. This 
is due to a high inflammatory profile of these samples, associated with a high 
tumor percentage of stoma.  It is not unexpected that diabetic patients could have 
an increased inflammatory status, consequence of diabetes itself. A chronic 
inflammatory status in the diabetic group, may lead to an increase in fibrotic tissue, 
which could justify the increased stroma found in these patients. It is accepted that 
metabolic impaired patients may have worse prognosis to a variety of conditions, 
as is the case of cancer. However, we did not find any significant differences in the 
overall survival between diabetic and non-diabetic patients both in a follow up 
period of 2 and 5 years. Also, we did not find any correlation between overall 
survival and the GMS status of the patients. This is probably due to low number of 
patients included in our cohort. Also, as our lower GMS values is mainly associated 
with the diabetic patients, with increased TSP, it may suggest that the tumor 
microenvironment is desmoplastic which may complicate the treatment options, 
and may demand a more aggressive therapeutic strategy, such as more extensive 
surgery.  In this paper, an inflammatory status, translated by a high KM is regarded 
as a more beneficial environment and associated with a better prognosis. The 
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worse prognosis of diabetic patients which is described in the literature, despite 
the higher inflammatory microenvironment, may be due to a macrophage 
polarization towards a M2 phenotype. 
We also thought of evaluating the systemic inflammation through the 
assessment of the Glasgow Prognostic Score, which combines albumin and C-
reactive protein into a risk stratification score for predicting clinical outcome in 
patients with cancer 
88
. We did not find any significant differences between the 
experimental groups and in the overall survival. This is probably due to, although 
the diabetic patients present a low chronic inflammatory state this is overcome by 
the tumor-associated inflammation, present in both groups.  
We have found lower microvessel density in the diabetic group when 
compared to the control groups. And, more surprisingly, we found that the tumors, 
in both experimental groups, had lower microvessel density than the normal 
adjacent mucosa. This is in accordance with the results obtained for the TSP 
involvement in the tumors. A more desmoplastic tumor environment is associated 
with lower vascularization and higher fibrotic tissue, which was found with the 
Sirius Red staining 
65,229
. However, we would like to further confirm the CD31 results 
with different evaluation methods such as another endothelial marker (i.e. CD34), 
or different image assessment method. 
Although we have found no significant differences in overall survival 
between diabetic and non-diabetic patients we believe that this is mainly due to the 
low number of patients in our experimental groups and the lack of representation 
of more cases of gastric cardia tumors. Furthermore, when the patients were 
subdivided according to their GMS or GPS score, the N of the experimental groups 
further decreased, decreasing also the strength of the analysis.  Further work is 
needed in order to confirm the obtained data and increase the statistical 
significance of the obtained results. 
 
  
 
 
 
 
Conclusion and future 
perspectives
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In conclusion, although not significant, we observe differences between the 
groups and between the tumor and the normal adjacent areas. DM2 changes both 
systemic and tumoral inflammatory profiles of the patients, as well as the 
angiogenic profile in tumor and peri-tumoral areas. This work raised many 
questions, and will need further research in order to fully understand the effect of 
metabolic disturbances in the development and progression of gastric cancer. 
We will continue our work by: 
- increasing our cohort; 
- confirming the results obtained by CD31 staining, through another 
endothelial cell marker, or measure of the vessel size or diameter, or even evaluate 
the microvessel density with another imaging technique; 
- evaluating oxidative stress, by immunohistochemistry against 3-
Nitrotyrosine (currently in process of optimization of the antibody); 
- evaluating the polarization of macrophages (M0, M1 and M2) to verify if 
the population of immune cells in the tumor have a pro- or anti-inflammatory 
profile. 
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